Chemomab Therapeutics (CMMB) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Environment Environmental Intensity LEED Materials Nature Nuclear Offset Package Packaging Pandemic Recycling Toxic Access African American Asian Attrition Benefits Black California Consumer Privacy Act Collective Bargaining Community Customer Cyber Data Privacy Death Demographic Disability Diversity Drug Pricing Employee Employee Retention Employee Training Engagement Ethnicity Gender General Data Protection Regulation Health Care Healthcare Hire Hiring Hispanic Human Capital Human Resources Incident Injuries Injury Latinx LGBTQ Perquisites Privacy Product Quality Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skill Skills Social Stakeholder Supplier Supply Chain Talent Training Union Volunteer Women Assessment Assurance Audit Bonus Bribe Bribery Chronic Classified Clawback Commitment Corporate Governance Department of Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Innovation Innovative Investigation Lawsuit Leadership Litigation Long-term Majority Oversee Oversight Perquisite Plaintiff Purpose R&D Reputation Reputational Research and Development Responsibility Responsible Shareholder Proposals Special Meeting Strategy Targets Tax Tenure Transparency Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

2022 Annual Meeting of Shareholders

On June 7, 2022, Chemomab Therapeutics Ltd. (the “Company”) held its 2022 Annual Meeting of Shareholders (the “Annual Meeting”). There were 84,756,220 ordinary shares, no par value, of the Company (equivalent to 4,237,811 American Depositary Shares, each representing twenty (20) ordinary shares) represented in person or by proxy at the Annual Meeting, constituting approximately 37.16% of the outstanding ordinary shares on April 28, 2022, the record date for the Annual Meeting.

The matters voted upon at the Annual Meeting and the final results of such voting are set forth below:

Proposal 1: To re-elect Dr. Nissim Darvish to serve as a Class I director of the Company to hold office until our 2025 annual general meeting of shareholders or until his successor is duly elected and qualified or until his earlier death, resignation or removal.

FOR		AGAINST		ABSTAIN
84,055,680		591,060		109,480

In accordance with the Company’s definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”) on April 28, 2022, the Company originally proposed the re-election of Mr. Joel Maryles as a Class I director. On May 31, 2022, and as reported on the Current Report on Form 8-K filed with the SEC on June 1, 2022, Mr. Maryles notified the board of directors of the Company that he will not stand for re-election at the Annual Meeting, and therefore the Company did not tabulate any votes received in connection with Mr. Maryles’ re-election as a Class I director.

Proposal 2: To approve an amendment to the terms of compensation of Dr. Adi Mor, the Company’s Co-Founder, Chief Scientific Officer and Class III Director.

FOR		AGAINST		ABSTAIN
83,840,260		894,060		21,900

The amendment to the terms of engagement of Dr. Adi Mor, the Company’s Chief Scientific Officer, which was approved under Proposal 2 is further described in the Proxy Statement.

- 2 -

Proposal 3: To grant additional equity grants to certain of the Company's directors and certain changes to the Company’s director compensation package, all in compliance with the Company's Compensation Policy.

As previously reported by the Company under additional proxy materials on Schedule 14A, which was filed with the SEC on May 31, 2022, the board of directors of the Company resolved to withdraw Proposal 3 and, therefore, the Company did not tabulate any votes received in connection therewith.

Proposal 4: The approval of the reappointment of Somekh Chaikin, a member of KPMG International, as the Company’s independent auditors and to authorize the board of directors of the Company to delegate to the audit committee the authority to fix the said independent auditors’ remuneration in accordance with the volume and nature of their services.

FOR		AGAINST		ABSTAIN
84,152,640		489,980		113,600

- 3 -